Ablynx reports positive Phase I trial results of caplacizumab to treat TTP

Ablynx has reported positive results from the Phase I trial of its anti-von Willebrand factor Nanobody caplacizumab to treat acquired thrombotic thrombocytopenic purpura (TTP).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news